From: NT-proBNP as a predictor of death and cardiovascular events in patients with type 2 diabetes
Clinical parameter | Effect on circulating BNP/NT-proBNP |
---|---|
Age | Increase [23] |
Female gender | Increase [23] |
African Americans | Decrease [24] |
Obesity | |
Hypertension | Increase [52] |
Coronary heart disease | Increase [53] |
Left ventricular systolic dysfunction | |
Atrial fibrillation | Increase [55] |
Renal insufficiency | Increase [56] |
Hepatic disease | Increase [57] |
Metformin | |
Pioglitazone | |
DPP-4i | Unchanged [41] |
SGLT2 inhibitors | |
GLP-1 RA | |
Sulfonylureas | Increase [50] |
Insulin | |
ACE inhibitors | Decrease [58] |
Beta-blockers |